Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.

PubWeight™: 1.42‹?› | Rank: Top 5%

🔗 View Article (PMID 22782301)

Published in Graefes Arch Clin Exp Ophthalmol on July 11, 2012

Authors

Henrike Westekemper1, Michael Freistuehler, Norbert Bornfeld, Klaus-Peter Steuhl, Max Scheulen, Ralf A Hilger

Author Affiliations

1: Department of Ophthalmology, University Hospital Essen, Hufelandstr. 55, 45122 Essen, Germany.

Articles cited by this

New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36

Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res (1999) 5.35

BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst (2006) 3.61

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58

The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res (1999) 3.36

The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80

A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem (2001) 1.94

Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res (2001) 1.79

The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res (2006) 1.65

Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci U S A (1998) 1.64

Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res (1999) 1.63

Death receptors and melanoma resistance to apoptosis. Oncogene (2003) 1.51

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res (2004) 1.51

Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res (2003) 1.45

Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol (2000) 1.40

Malignant melanoma of the conjunctiva. Hum Pathol (1985) 1.36

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer (2005) 1.32

Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. Graefes Arch Clin Exp Ophthalmol (2005) 1.28

Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res (1997) 1.27

Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett (2006) 1.19

Conjunctival malignant melanoma in Sweden 1969-91. Acta Ophthalmol (Copenh) (1992) 1.17

Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther (2006) 1.16

Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet (2000) 1.15

Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis (2003) 1.15

Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol (1998) 1.11

On the track of antitumour ribonucleases. Mol Biosyst (2005) 1.00

Establishment of two cell lines derived from conjunctival melanomas. Exp Eye Res (2005) 0.95

The proteasome: a novel target for anticancer therapy. Clin Transl Oncol (2006) 0.95

Nemorosone blocks proliferation and induces apoptosis in leukemia cells. Int J Clin Pharmacol Ther (2008) 0.88

Contribution of structural peculiarities of onconase to its high stability and folding kinetics. Biochemistry (2006) 0.87

Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). Br J Pharmacol (2011) 0.87

Novel antitumoral compound isolated from Clusia rosea. Int J Clin Pharmacol Ther (2003) 0.85

Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy. Expert Opin Biol Ther (2008) 0.81

Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie (2008) 0.79

Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agents. Int J Clin Pharmacol Ther (2011) 0.77

Chemosensitivity of conjunctival melanoma cell lines to single chemotherapeutic agents and combinations. Br J Ophthalmol (2012) 0.76

[Bortezomib]. Dtsch Med Wochenschr (2006) 0.75

Articles by these authors

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12

Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment: a prospective randomized multicenter clinical study. Ophthalmology (2007) 3.47

Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res (2003) 2.18

Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet (2013) 2.05

Choroidal metastasis in disseminated lung cancer: frequency and risk factors. Am J Ophthalmol (2002) 1.86

Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res (2013) 1.84

Primary vitrectomy for rhegmatogenous retinal detachment: an analysis of 512 cases. Graefes Arch Clin Exp Ophthalmol (2005) 1.79

GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology (2009) 1.67

Comparison of the Colvard, Procyon, and Neuroptics pupillometers for measuring pupil diameter under low ambient illumination. J Refract Surg (2010) 1.53

Hypothermia does not alter somatosensory evoked potential amplitude and global cerebral oxygen extraction during marked sodium nitroprusside-induced arterial hypotension. Anesthesiology (2003) 1.53

Amniotic membrane grafts for nontraumatic corneal perforations, descemetoceles, and deep ulcers. Ophthalmology (2002) 1.48

Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One (2013) 1.45

Decreased keratocyte death after laser-assisted subepithelial keratectomy and photorefractive keratectomy in rabbits. J Cataract Refract Surg (2004) 1.39

Biopsy in indeterminate intraocular tumors. Ophthalmology (2002) 1.37

Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology (2007) 1.33

External beam radiotherapy of choroidal metastases--final results of a prospective study of the German Cancer Society (ARO 95-08). Radiother Oncol (2002) 1.32

Amniotic membrane transplantation in the human eye. Dtsch Arztebl Int (2011) 1.26

Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer (2005) 1.22

Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol (2002) 1.22

Implantation and explantation of a wireless epiretinal retina implant device: observations during the EPIRET3 prospective clinical trial. Invest Ophthalmol Vis Sci (2009) 1.21

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant (2010) 1.12

Primary intraocular lymphoma of T-cell type: report of a case and review of the literature. Graefes Arch Clin Exp Ophthalmol (2004) 1.12

Visual loss following intraocular gas injection. Dtsch Arztebl Int (2008) 1.09

Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol (2004) 1.08

Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies. Acta Ophthalmol Scand (2004) 1.06

A method and technical equipment for an acute human trial to evaluate retinal implant technology. J Neural Eng (2005) 1.04

Histopathologic findings of eyes enucleated after treatment with chemosurgery for retinoblastoma. Open Ophthalmol J (2011) 1.03

Expression of HSP 90, PTEN and Bcl-2 in conjunctival melanoma. Br J Ophthalmol (2010) 1.02

Matrix metalloproteinases (MMP-2 and 9) and tissue inhibitors of matrix metalloproteinases (TIMP-1 and 2) during the course of experimental necrotizing herpetic keratitis. Exp Eye Res (2003) 1.01

Angioarchitecture and innervation of the primate anterior episclera. Curr Eye Res (2005) 1.00

Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study. Ophthalmology (2008) 1.00

Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur J Haematol (2004) 0.98

Intraocular biopsy using special forceps: a new instrument and refined surgical technique. Br J Ophthalmol (2011) 0.97

Amniotic membrane transplantation induces apoptosis in T lymphocytes in murine corneas with experimental herpetic stromal keratitis. Invest Ophthalmol Vis Sci (2009) 0.96

Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res (2005) 0.96

Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology (2002) 0.95

Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol (2004) 0.95

On the influence of neutrophils in corneas with necrotizing HSV-1 keratitis following amniotic membrane transplantation. Exp Eye Res (2007) 0.94

Antiproliferative effect of mycophenolate mofetil on cultured human Tenon fibroblasts. Graefes Arch Clin Exp Ophthalmol (2002) 0.94

Squamous cell carcinoma of the conjunctiva in patients with atopic eczema. Cornea (2003) 0.92

Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina (2005) 0.91

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. Anticancer Drugs (2009) 0.91

Combined phacoemulsification and pars plana vitrectomy: clear corneal versus scleral incisions: prospective randomized multicenter study. J Cataract Refract Surg (2003) 0.91

The treatment of wet age-related macular degeneration. Dtsch Arztebl Int (2009) 0.91

Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma. Graefes Arch Clin Exp Ophthalmol (2005) 0.91

Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model. Blood (2006) 0.91

Comparison of cryopreserved and air-dried human amniotic membrane for ophthalmologic applications. Graefes Arch Clin Exp Ophthalmol (2009) 0.90

The contribution of plukenetione A to the anti-tumoral activity of Cuban propolis. Bioorg Med Chem (2008) 0.90

Episcleral venous pressure in untreated primary open-angle and normal-tension glaucoma. Ophthalmologica (2005) 0.90

Assessment of genomic instability in breast cancer and uveal melanoma by random amplified polymorphic DNA analysis. Int J Cancer (2002) 0.89

Case-control study on uveal melanoma (RIFA): rational and design. BMC Ophthalmol (2004) 0.88

Obstructive sleep apnea syndrome, normal tension glaucoma, and nCPAP therapy--a short note. Sleep (2003) 0.88

Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). Br J Pharmacol (2011) 0.87

Topical treatment with antisense oligonucleotides targeting tumor necrosis factor-alpha in herpetic stromal keratitis. Invest Ophthalmol Vis Sci (2003) 0.87

Cell death sensitization of leukemia cells by opioid receptor activation. Oncotarget (2013) 0.86

Second cranio-facial malignancies in hereditary retinoblastoma survivors previously treated with radiation therapy: clinic and radiologic characteristics and survival outcomes. Eur J Cancer (2013) 0.86

Angiographic findings following tack fixation of a wireless epiretinal retina implant device in blind RP patients. Graefes Arch Clin Exp Ophthalmol (2011) 0.86

Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. Cancer Chemother Pharmacol (2007) 0.86

Novel cell lines derived by long-term culture of primary uveal melanomas. Ophthalmologica (2009) 0.86

[Endogenous bacterial endophthalmitis: a retrospective study on 22 consecutive cases]. Klin Monbl Augenheilkd (2004) 0.85

Conjunctival macrophage-mediated influence of the local and systemic immune response after corneal herpes simplex virus-1 infection. Immunology (2002) 0.85

Scanning laser polarimetry in myopic and hyperopic subjects. Graefes Arch Clin Exp Ophthalmol (2004) 0.85

A new tool for the transfection of corneal endothelial cells: calcium phosphate nanoparticles. Acta Biomater (2011) 0.85

Amniotic membrane induces peroxisome proliferator-activated receptor-γ positive alternatively activated macrophages. Invest Ophthalmol Vis Sci (2012) 0.84

Acute electrical stimulation of the human retina with an epiretinal electrode array. Acta Ophthalmol (2011) 0.84

The impact of diagnosis and plaque radiotherapy treatment of malignant choroidal melanoma on patients' quality of life. Psychooncology (2006) 0.84

Influence of cataract surgery with implantation of different intraocular lenses on scanning laser tomography and polarimetry. Am J Ophthalmol (2003) 0.84

Risk of uveal melanoma. Ophthalmology (2007) 0.84

Quality of life in patients with malignant choroidal melanoma after radiotherapy. Graefes Arch Clin Exp Ophthalmol (2003) 0.84

Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma. Cancer Med (2013) 0.84

Long-term results after surgical extraction of subfoveal choroidal neovascular membranes with and without haemorrhage in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2004) 0.83

Mobile phone use and risk of uveal melanoma: results of the risk factors for uveal melanoma case-control study. J Natl Cancer Inst (2009) 0.83

Effects of the human amniotic membrane on axonal outgrowth of dorsal root ganglia neurons in culture. Curr Eye Res (2007) 0.83

Development of surgical techniques for implantation of a wireless intraocular epiretinal retina implant in Göttingen minipigs. Graefes Arch Clin Exp Ophthalmol (2011) 0.82

Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines. Invest Ophthalmol Vis Sci (2008) 0.82

[Brivudine as an alternative systemic therapy to aciclovir and ganciclovir in acute retinal necrosis syndrome due to varicella-zoster virus]. Klin Monbl Augenheilkd (2003) 0.82

Cooking and uveal melanoma risk: results from two German case-control studies. Cancer Causes Control (2003) 0.82

Pharmacokinetic properties of succinylmonocholine in surgical patients. J Anal Toxicol (2011) 0.82

Monte Carlo simulations applied to conjunctival lymphoma radiotherapy treatment. Strahlenther Onkol (2011) 0.81

Population-based incidence estimates of uveal melanoma in Germany. Supplementing cancer registry data by case-control data. Eur J Cancer Prev (2006) 0.81

Chronically implanted epidural electrodes in Göttinger minipigs allow function tests of epiretinal implants. Graefes Arch Clin Exp Ophthalmol (2003) 0.81

Gene transfer to trabecular meshwork endothelium via direct injection into the Schlemm canal and in vivo toxicity study. Curr Eye Res (2005) 0.81

Loss at chromosome arm 16q in retinoblastoma: confirmation of the association with diffuse vitreous seeding and refinement of the recurrently deleted region. Genes Chromosomes Cancer (2011) 0.81

De novo intraocular retinoblastoma development after chemotherapy in patients with hereditary retinoblastoma. Retina (2006) 0.81

Beta-ray brachytherapy with 106Ru plaques for retinoblastoma. Int J Radiat Oncol Biol Phys (2006) 0.81

Rate of epithelialisation and re-operations in corneal ulcers treated with amniotic membrane transplantation combined with botulinum toxin-induced ptosis. Graefes Arch Clin Exp Ophthalmol (2007) 0.81

Photodynamic therapy using verteporfin for choroidal neovascularization associated with angioid streaks--long-term effects. Ophthalmic Res (2006) 0.80

Scanning laser topography and scanning laser polarimetry: comparing both imaging methods at same distances from the optic nerve head. Open Ophthalmol J (2012) 0.80

Amniotic membrane transplantation for reconstruction of corneal ulcer in graves ophthalmopathy. Cornea (2004) 0.80

Beta-ray brachytherapy of retinoblastoma: feasibility of a new small-sized ruthenium-106 plaque. Ophthalmic Res (2005) 0.80

Development of very large electrode arrays for epiretinal stimulation (VLARS). Biomed Eng Online (2014) 0.80

A case-control study: occupational cooking and the risk of uveal melanoma. BMC Ophthalmol (2010) 0.79

Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre. Br J Ophthalmol (2013) 0.79

Comparison of Spectralis-OCT, GDxVCC and GDxECC in assessing retinal nerve fiber layer (RNFL) in glaucomatous patients. Graefes Arch Clin Exp Ophthalmol (2012) 0.79

The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators. Med Phys (2004) 0.79